MindRank Announces $52 Million Series B Financing
Funding to advance MindRank’s AI-native drug R&D engine and innovative pipeline, including MDR-001, an oral small-molecule GLP-1 receptor agonist in Phase III clinical development in China HANGZHOU…
Read the full articleYou might also wanna read
“德睿智药”完成5200万美元B轮融资
36氪获悉，专注于AI驱动新药研发的科技公司“德睿智药”宣布分阶段完成累计5200万美元B轮融资，多家投资机构与产业基金共同投资。凯乘资本担任本轮融资独家财务顾问。本轮融资所得资金将核心投入公司自研全链路AI制药引擎MAP（Molecule Arts Platform）的深度技术
「德睿智药」获5200万美元B轮融资，AI设计的减肥药已进入3期临床｜36氪首发
文｜胡香赟 编辑｜海若镜 36 氪获悉，德睿智药近期已完成 5200 万美元B轮融资，投资方包括头部人民币和美元基金，凯乘资本为独家财务顾问。募集资金将用于AI制药引擎Molecule Arts Platform（MAP）升级迭代，完善其多智能体（Multi-Agent）协同体系
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·25d ago
A Chinese AI gains ground on the most powerful models of Claude and ChatGPT
Th US artificial intelligence models , which have comfortably dominated the market since the launch of ChatGPT, no longer seem so unattainab
Zhipu’s GLM-5.2 Now World’s Third Most Widely Used AI Model
Chinese start-up's latest tech soars in worldwide usage after jump in benchmark scores, suspension of latest Anthropic models
Aureka offers open-source AI module for drug discovery
Aureka offers open-source AI module for drug discovery Phil.Taylor Wed, 08/07/2026 - 13:18
Comments
Sign in to join the conversation.
No comments yet. Be the first.